Email this page: News Release

OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by OXiGENE, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps OXiGENE, Inc. prevent automated submissions.